2018
DOI: 10.1002/jsp2.1013
|View full text |Cite
|
Sign up to set email alerts
|

Discogenic cell transplantation directly from a cryopreserved state in an induced intervertebral disc degeneration canine model

Abstract: A multitude of studies has indicated the potential of cell therapy as a method for intervertebral disc (IVD) regeneration. Transplantation of a variety of cells has been assessed and shown capable of deterring the rate of degeneration in animal models and in human clinical trials. In this study, a novel approach using human discogenic nucleus pulposus cells directly from their cryopreserved state was assessed. In an established canine disc degeneration model, the degeneration process was evaluated in IVDs rece… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
48
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 29 publications
(48 citation statements)
references
References 44 publications
(79 reference statements)
0
48
0
Order By: Relevance
“…In the future, AF cell sheets might be applied in combination with NP cell therapy, [55][56][57] to further curtail or even reverse IVD degeneration. 10,58 Although our study provides evidence to the benefits of cell sheet technology for IVD repair, the study does have some limitations.…”
Section: Discussionmentioning
confidence: 99%
“…In the future, AF cell sheets might be applied in combination with NP cell therapy, [55][56][57] to further curtail or even reverse IVD degeneration. 10,58 Although our study provides evidence to the benefits of cell sheet technology for IVD repair, the study does have some limitations.…”
Section: Discussionmentioning
confidence: 99%
“…IDCT contains a mixture of specialized therapeutic progenitor cells engineered from donated adult disc tissue, or “discogenic” cells and a viscous carrier material. Promising animal data suggests a potential therapeutic benefit of IDCT, including disc height improvement and normalization of disc architecture, and a safe profile . Aesculap Biologics (Breinigsville, Pennsylvania) is currently testing NOVOCART DISC in a Phase II trial in the European Union.…”
Section: Current Commercial Approaches For Cell‐based Disc Repair Andmentioning
confidence: 99%
“…Promising animal data suggests a potential therapeutic benefit of IDCT, including disc height improvement and normalization of disc architecture, and a safe profile. 31 Aesculap Biologics (Breinigsville, Pennsylvania) is currently testing NOVOCART DISC in a Phase II trial in the European Union. This treatment is a combination of autologous disc chondrocytes and a self-polymerizing hydrogel (clinicaltrials.gov study identifier NCT01640457) that is already being used clinically for articular cartilage repair in the knee.…”
Section: Current Commercial Approaches For Cell-based Disc Repair Amentioning
confidence: 99%
“…7 Nevertheless, an optimal cell type or preconditioning method to enable optimized regeneration of NP tissue has not yet been established. [8][9][10] Wnt signaling holds a key role in joint development, homeostasis, and pathogenesis. The prominence of wnt signaling in cartilage tissues was initially discovered in chicken limb cartilage.…”
Section: Introductionmentioning
confidence: 99%